Search research articles
Contact Us
Filters
Showing results (11-20 of 135) with videos related to
Page
of 14
Sort By:
Pharmacological Reviews
|
February 15, 2001
The control of prostate-specific antigen expression and gene regulation by pharmacological agents
S C Dixon, K B Knopf, W D Figg
The Journal of Pathology
|
October 10, 2001
The androgen receptor gene and its influence on the development and progression of prostate cancer
J S Montgomery, D K Price, W D Figg
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
July 12, 2002
Thalidomide, an antiangiogenic agent with clinical activity in cancer
S S W Ng, M Brown, W D Figg
Cancer Research
|
November 4, 2000
Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer
K Salnikow, M Costa, W D Figg, et al.
Molecular Pharmacology
|
June 1, 1995
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells
R Danesi, W D Figg, E Reed, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
August 14, 2001
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry
E W Woo, R Messmann, E A Sausville, et al.
Oncology Reports
|
June 19, 1998
A phase II study of bromocriptine in patients with androgen-independent prostate cancer
J Horti, W D Figg, B Weinberger, et al.
Neoplasma
|
August 31, 1999
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma
I N Arah, S C Dixon, J Horti, et al.
International Journal of Oncology
|
March 17, 2001
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines
M V Blagosklonny, S C Dixon, R Robey, et al.
Urology
|
August 11, 1998
Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
O Sartor, M Weinberger, A Moore, et al.
Page
of 14
Search research articles
Search
Showing results (11-20 of 135) with videos related to
Sort By:
Page
of 14
Pharmacological Reviews
|
February 15, 2001
The control of prostate-specific antigen expression and gene regulation by pharmacological agents
S C Dixon, K B Knopf, W D Figg
The Journal of Pathology
|
October 10, 2001
The androgen receptor gene and its influence on the development and progression of prostate cancer
J S Montgomery, D K Price, W D Figg
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
July 12, 2002
Thalidomide, an antiangiogenic agent with clinical activity in cancer
S S W Ng, M Brown, W D Figg
Cancer Research
|
November 4, 2000
Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer
K Salnikow, M Costa, W D Figg, et al.
Molecular Pharmacology
|
June 1, 1995
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells
R Danesi, W D Figg, E Reed, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
August 14, 2001
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry
E W Woo, R Messmann, E A Sausville, et al.
Oncology Reports
|
June 19, 1998
A phase II study of bromocriptine in patients with androgen-independent prostate cancer
J Horti, W D Figg, B Weinberger, et al.
Neoplasma
|
August 31, 1999
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma
I N Arah, S C Dixon, J Horti, et al.
International Journal of Oncology
|
March 17, 2001
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines
M V Blagosklonny, S C Dixon, R Robey, et al.
Urology
|
August 11, 1998
Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
O Sartor, M Weinberger, A Moore, et al.
Page
of 14